Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
NCT ID: NCT00815659
Last Updated: 2011-08-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
97 participants
INTERVENTIONAL
2008-12-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rosuvastatin
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
rosuvastatin
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rosuvastatin
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LDL-Cholesterol \> 130mg/dl
* HDL-Cholesterol \< 40mg/dl in males and \<50mg/dl in females
* Triglycerides \< 400 mg/dl
Exclusion Criteria
* Currently under statin therapy or previously treated with statins within the last 6 months
18 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dilek Ural, MD, Prof
Role: PRINCIPAL_INVESTIGATOR
Kocaeli University Faculty of Medicine Cardiology Dept
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research site
Ankara, Besevler, Turkey (Türkiye)
Research site
Kayseri, Erciyes, Turkey (Türkiye)
Research site
Istanbul, Haseki, Turkey (Türkiye)
Research site
Kocaeli, Umuttepe, Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Trabzon, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D3560L00079
Identifier Type: -
Identifier Source: org_study_id